Intranasal vasopressin administration is being explored as an intervention for autism.

“and I think you know one thing the reason why we did this work is and I think it speaks to what you said earlier is there is an urgency on the part of parents to say you know my child's brain is developing right and and there's a sense of that them you know by the sort of Western model has failed a lot of people you know they look to doctors and say what are what are the solutions and doctors will say well we have a limited number of tools in the toolkit here we just don't know right and so you know one of the reasons why they did that big oxytocin study was that people were trying to get the oxytocin anyway so it was like let's just make sure that this is safe let's see if it's effective and so some of our thinking was you know as soon as some of this work hits you know like it get and some of the work is been covered by the media and so you know our feeling was we can give this intranasal um and we can do it under safe monitoring ways um and so people are going to think about doing these things anyway so let's just make sure that this is safe and let's test this in a rigorous way”

“so we were able to have what's called um converg in validity right so it's a fancy scientific term to say do all these measures that we think should be related are they related and are we seeing the same thing and um the answer was yes”

“um and then it was randomized Placebo controlled um and then we basically gave um vasor presson again twice a day for four weeks um to children they were about 6 to 12 years of age”